neuropsychologists

T-cell receptor

Vidofludimus Calcium Effective in Patients With Relapsing-Remitting MS

Vidofludimus calcium treatment reduces new lesions in patients with relapsing-remitting multiple sclerosis (RRMS), according to results from the phase 2 EMPhASIS clinical trial that were published in Annals of Clinical and Translational Neurology. The treatment is also well-tolerated and has a favorable safety profile, according to the trial results. “Assessment in longer, larger trials is…

Myocardial Infarction

Patients With NMOSD and MS Show Higher Risk of Myocardial Infarction

The risk of myocardial infarction is increased in patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), according to a new study published in the Multiple Sclerosis Journal. The risk seems to be the same between the 2 conditions. To determine the risk of myocardial infarction in this patient group, a team of…

woman covid

COVID-19 Severity Linked With Neurologic Worsening in MS

The severity of COVID-19 and a lack of complete recovery are associated with new or worsening neurological symptoms in some patients with multiple sclerosis (MS) and related disorders, according to a new study published in Multiple Sclerosis and Related Disorders.  This finding is important and suggests that these patients could be primary candidates for anti-SARS-CoV-2…

retinal

Retinal Layer Thinning Predicts Long-Term Disability in MS

Researchers discovered that ganglion cells plus the inner plexiform layer (GCIPL) and peripapillary retinal nerve fiber layer (pRNFL) measurements predict physical and cognitive neurodegeneration in patients with multiple sclerosis (MS) after 6 years, as published in the Multiple Sclerosis Journal. GCIPL and pRNFL thinning correlate with physical and cognitive disability progression and are established biomarkers…

brain scan

Higher sNfL Levels Predict Grey Matter Atrophy in Long-Term MS Study

Higher serum neurofilament light chain (sNfL) levels during periods of active inflammation predicted reduced grey matter volume, deep grey matter volume, and cortical thickness 10 years later in patients with relapsing-remitting multiple sclerosis (RRMS), according to a new study published in the Journal of Neurology, Neurosurgery & Psychiatry. The researchers also found an association between…

Intravenous therapy

FDA Extends PDUFA Goal Date of Ublituximab for MS

The US Food and Drug Administration (FDA) extended the Prescription Drug User Fee Act (PDUFA) goal date for ublituximab to December 28, 2022, as announced in a press release by TG Therapeutics. Formerly known as TG-1101, ublituximab is an investigational monoclonal antibody to treat multiple sclerosis (MS). It targets CD20-expressing B-cells that are designed to…

MRI imaging

Researchers Recommend Adding 3D FLAIR Sequences to MRI Protocol for MS

The use of 3D fluid-attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI) sequencing detects significantly more multiple sclerosis (MS) brain lesions than 2D FLAIR sequencing, according to a study published in the Egyptian Journal of Radiology and Nuclear Medicine. The study also found that using maximum intensity projection (MIP) on the 3D FLAIR images enabled…

Human brain scan

Cognitive Impairment Correlates With Decreased Thalamic Volume in MS

Cognitive impairment correlated strongly with reduced thalamic volume and temporal lobe cortical thickness in patients with pediatric-onset multiple sclerosis (MS), according to findings published in the Egyptian Journal of Neurology, Psychiatry and Neurosurgery. Researchers analyzed the level of cognitive impairment as it related to brain volumetric measurements of 50 patients with pediatric-onset MS ranging from…

Next post in MS News Briefs